RxDoctor Payments Data

Tiffany Huxman, APRN

Psychiatric/Mental Health · Newton, KSNPI 1609007228

Payments from drug & device makers

$756in general payments, 2019–2025

Across 40 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$123
  • Johnson & Johnson$103
  • Alkermes, Inc.$95
  • Neurocrine Biosciences, Inc.$69
  • AbbVie$69
  • Takeda Pharmaceuticals U.S.A., Inc.$61
  • plus $237 from 9 others

What the payments were for

  • Food & beverage$756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$756 in reported general payments places this provider in the 55th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$24,124
Medicare patients
84
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate23$79,098
RexultiBrexpiprazole26$40,743
VraylarCariprazine Hcl13$18,441
Lurasidone Hcl36$10,232
TrintellixVortioxetine Hydrobromide12$5,288
Paliperidone ErPaliperidone27$4,647
Lamotrigine OdtLamotrigine12$3,332
Vilazodone Hcl40$2,999
Asenapine Maleate17$2,601
Aripiprazole52$2,440
Clozapine17$1,631
Oxcarbazepine42$1,515
Quetiapine Fumarate127$1,469
Venlafaxine Hcl ErVenlafaxine Hcl143$1,430
Fluvoxamine Maleate39$1,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$103$79,09823 claims
Otsuka America Pharmaceutical, Inc.Rexulti$33$40,74326 claims
AbbVieVraylar$69$18,44113 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$61$5,28812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Newton

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →